Sphere Fluidics, a University of Cambridge life sciences spin-out, has received £1.6m ($2.5m) in a series A round led by private equity firm 24Haymarket and joined by the Royal Society and the University of Cambridge.
Also backing the round were Cambridge Enterprise Limited, Providence Investment Company Limited, the London Business Angels Roundtable EIS Fund, and a number of independent angel backers.
It was the first venture round for Sphere Fluidics.
The Cambridge-based life sciences firm specialises in the analysis and detection of single cells and their biomolecules. Sphere’s technology enables, amongst other things, the study of the mechanism that causes chemotherapy resistance in cancerous cells.
Andrew Mackintosh , chairman of Sphere Fluidics and the former chief executive officer (CEO) of a number of Oxford and Cambridge spin-outs including Oxford’s first spin-out, Oxford Instruments, is also the CEO of the Royal Society Enterprise Fund.
He said: “Sphere Fluidics is exactly the…
